Circulating Tumor DNA May Be Predictive of Disease Progression in Patients with Rectal Cancer
PHILADELPHIA — Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemoradiotherapy was associated with poor response and increased risk...
Search/Filter
Loading...
The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer Research
PHILADELPHIA, PA and CAMBRIDGE, MA – Two grants for research that could transform cancer therapies have been funded through...
The AACR and St. Baldrick’s Foundation Partner on a New Scientific Achievement Award and Grant to Support Pediatric Cancer Research
The American Association for Cancer Research and the St. Baldrick’s Foundation are pleased to announce the creation of the AACR-St....
Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer
Study also indicated that a lack of ctDNA may signal improved outcomes for patients SAN ANTONIO — The presence...
Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type
SAN ANTONIO — A large meta-analysis of breast cancer patients showed that residual cancer burden after neoadjuvant chemotherapy is...
Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
SAN ANTONIO — Metastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better...
Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women
Estrogen alone decreased, while adding progestin increased, breast cancer incidence SAN ANTONIO — Long-term follow-up results from two large,...
AACR Applauds Confirmation of Stephen M. Hahn, MD, as FDA Commissioner
Hahn has shown a commitment to science-directed and patient-focused policies PHILADELPHIA — The American Association for Cancer Research (AACR),...
MINDACT Trial Data Reveal Certain Women With Luminal Breast Cancer May Be Undertreated With Tamoxifen Alone
SAN ANTONIO — Among women with hormone receptor (HR)-positive, HER2-negative breast cancer with a high clinical risk (determined by tumor...
Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer
SAN ANTONIO — The addition of the anti-PD-L1 immunotherapeutic atezolizumab (Tecentriq) to neoadjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) did...